The Growth Hormone Stack: CJC-1295 + Ipamorelin in Practice

Endogenous growth hormone secretion follows a pulsatile pattern. Most of the daily growth hormone output happens in two or three large pulses, the largest of which occurs in the first 90 minutes of deep sleep. As we age, those pulses get smaller and less frequent. By age 40, peak nocturnal growth hormone amplitude has typically dropped to roughly half of what it was at 25. By 60, it is a quarter.

The research case for amplifying endogenous growth hormone pulses (rather than supplying exogenous recombinant human growth hormone) rests on two arguments. First, pulsatile signaling is biologically distinct from steady-state elevation — pulsatile growth hormone activates regenerative and metabolic pathways that continuous infusion does not. Second, the secretagogue approach preserves the body's own feedback regulation, which essentially eliminates the dysregulation risks that direct injection of recombinant human growth hormone carries.

The CJC-1295 plus ipamorelin combination is the most-studied research approach to this problem. The two compounds operate on different sides of the growth hormone secretion machinery. Together they produce larger growth hormone pulses than either alone — without producing the steady-state elevation that creates regulatory and side-effect problems.

How the stack works

Growth hormone secretion is regulated by two upstream signals from the hypothalamus. **GHRH** (growth hormone-releasing hormone) tells the pituitary to release growth hormone; **somatostatin** tells it to stop. The two oscillate, producing the pulsatile pattern.

A third signal — **ghrelin** — comes from the gut and amplifies the growth hormone response when GHRH is also present. Synthetic ghrelin mimetics produce the same effect.

CJC-1295 is a 30-amino-acid GHRH analog. It binds the GHRH receptor on pituitary cells, instructing them to release growth hormone. The "1295" version has a chemical modification that extends its half-life dramatically — from about 7 minutes for native GHRH to roughly 8 days for CJC-1295.

Ipamorelin is a pentapeptide ghrelin mimetic. It binds the ghrelin receptor and amplifies the growth-hormone-releasing signal — but unlike older ghrelin mimetics, ipamorelin is highly selective. It does not significantly elevate cortisol or prolactin. That selectivity matters because the older mimetics' off-target effects are why the field shifted away from them.

When you combine a GHRH analog with a selective ghrelin mimetic, the growth hormone pulse is larger than either alone. The two signals are complementary, not redundant.

What the human data shows

The human evidence on this combination is more limited than for the GLP-1 family, but several anchor points exist:

**CJC-1295 mechanism in healthy adults (JCEM 2006).** Teichman et al. published the foundational pharmacokinetic and pharmacodynamic data on CJC-1295 in healthy adults. Single-dose administration produced sustained elevations in pulsatile growth hormone and IGF-1 (a downstream growth signal) lasting over a week. The pulsatile pattern of growth hormone was preserved — concentrations rose during natural pulse windows and returned toward baseline between them.

**Ipamorelin selectivity (European Journal of Endocrinology 1999).** Raun et al. characterized ipamorelin and demonstrated its selective growth hormone release without the cortisol or prolactin elevation that limits older ghrelin mimetics.

**Tesamorelin in HIV-associated lipodystrophy (NEJM 2007, JCEM 2008).** Tesamorelin — a structurally similar GHRH analog — produced significant reductions in visceral adipose tissue and improvements in the lipid profile in adults with HIV-associated visceral fat accumulation. This is the strongest human clinical trial dataset for the GHRH-analog approach to body composition.

**Sermorelin in adult growth-hormone-deficient patients.** Sermorelin (an older, shorter-acting GHRH analog) has phase 3 data showing improved body composition, lipid profile, and quality-of-life measures in growth-hormone-deficient adults.

What users report

Two findings dominate the user-reported experience and they are worth taking seriously because the mechanism story supports both:

**Sleep quality.** This is the most-reported acute effect, and the one that surprises new users. The first growth hormone pulse of the night occurs in the first 90 minutes of deep sleep. CJC-1295 plus ipamorelin amplifies this pulse. Users describe deeper, less fragmented sleep within days of starting — often before any body composition change is detectable.

The wearable-data evidence (Oura, WHOOP, etc.) accumulating in the longevity research community supports this. Slow-wave sleep duration tends to increase by a meaningful margin in the first two weeks. Restorative sleep is the underrated intervention in this entire category — and it is a feature, not a bug, of how the growth hormone stack works.

**Body composition recomposition.** The pattern users describe — and this is the part the surface-level summary misses — is body recomposition rather than weight loss. Lean mass holds or increases; fat mass slowly decreases; the scale does not move dramatically but body composition shifts. This is consistent with the mechanism (growth hormone and IGF-1 are anabolic signals; the metabolic effect is secondary).

For someone whose primary goal is total weight loss, this is the wrong tool — the GLP-1 family is. For someone whose primary goal is improving the ratio of lean to fat mass, recovering training capacity, or supporting connective tissue, this is the right tool.

The angle most people miss

Here is the thing the marketing literature does not say:

The CJC-1295 plus ipamorelin stack is interesting not because it raises growth hormone levels, but because it preserves the pattern of growth hormone secretion. This is genuinely different from injecting recombinant human growth hormone directly.

When you give exogenous recombinant human growth hormone, you produce a steady-state elevation. That steady-state elevation has well-documented downsides — eventually, IGF-1-driven cell signaling pathways become dysregulated, glucose handling deteriorates, fluid retention emerges. The literature on long-term use of injected growth hormone in non-deficient adults is mixed at best.

The secretagogue approach is fundamentally different. The pulses are amplified, but the pattern — the rise and fall — is preserved. The body's negative feedback regulation through somatostatin is preserved. This is why the safety profile in the human data is substantially cleaner than direct injection at any dose that produces equivalent IGF-1 elevation.

Practical considerations

Three things to understand:

**Time horizon.** Sleep effects appear in days. Subjective recovery and joint-feel changes appear in weeks. Body composition changes appear over months. People who expect this to operate on the GLP-1 family's timescale (weeks to dramatic results) leave disappointed. People who treat it as a multi-month intervention typically do not.

**Stacking with training.** The anabolic signaling from elevated IGF-1 is highly responsive to mechanical loading. The body composition response to this stack in users who are doing structured resistance training is substantially better than in users who are not. This is a stack that rewards the work done outside the research protocol.

**Reconstitution and storage.** Both compounds are lyophilized, both are reconstituted with bacteriostatic water, both store at 36 to 46 degrees Fahrenheit.

Both compounds are stocked through our laboratory partner network at research-grade purity. Each batch is HPLC and mass spectrometry verified. Certificates of Analysis available on every SKU.